European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a special purpose acquisition company formed to identify and merge with a target operating in the European biotechnology and life sciences sector. EBAC completed its initial public offering in 2021 and filed its annual report on Form 10-K with the Securities and Exchange Commission on February 28, 2023, covering the fiscal year ended December 31, 2022. At the time of the filing, the company remained in its search phase, evaluating potential acquisition candidates across the European biotech landscape. To access full filing history, sponsor details, deal-tracking analytics, and real-time status updates for EBAC, sign up for a free account at SpacDesk.